PBE:NYE-Invesco Dynamic Biotechnology & Genome ETF (USD)

ETF | Health |

Last Closing

USD 68.92

Change

+0.91 (+1.34)%

Market Cap

N/A

Volume

6.10K

Analyst Target

N/A
Analyst Rating

N/A

ducovest Verdict

Verdict

About

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2025-01-08 )

Largest Industry Peers for Health

Symbol Name Price(Change) Market Cap
XLV Health Care Select Sector SPDR..

+0.72 (+0.52%)

USD 36.67B
FHLC Fidelity® MSCI Health Care In..

+0.38 (+0.57%)

USD 2.62B
FXH First Trust Health Care AlphaD..

+0.45 (+0.42%)

USD 1.09B
XHE SPDR® S&P Health Care Equipme..

+0.44 (+0.48%)

USD 0.21B
IDNA iShares Genomics Immunology an..

-0.42 (-1.78%)

USD 0.12B
SBIO ALPS Medical Breakthroughs ETF

-0.63 (-1.88%)

USD 0.11B
XHS SPDR® S&P Health Care Service..

+0.79 (+0.84%)

USD 0.07B
HTEC Robo Global® Healthcare Techn..

+0.20 (+0.69%)

USD 0.05B
BBP Virtus LifeSci Biotech Product..

-0.43 (-0.70%)

USD 0.02B
BBC Virtus LifeSci Biotech Clinica..

-0.38 (-1.54%)

USD 8.55M

ETFs Containing PBE

WBIR 0.00 % 1.25 %

N/A

N/A

Market Performance

  Market Performance vs. Industry/Classification (Health) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 3.59% 90% A- 89% A-
Dividend Return N/A N/A N/A N/A N/A
Total Return 3.59% 90% A- 89% A-
Trailing 12 Months  
Capital Gain 5.09% 71% C- 52% F
Dividend Return 0.05% 13% F N/A F
Total Return 5.14% 76% C+ 41% F
Trailing 5 Years  
Capital Gain 24.79% 57% F 63% D
Dividend Return 0.14% 11% F N/A F
Total Return 24.92% 43% F 52% F
Average Annual (5 Year Horizon)  
Capital Gain 5.84% 67% D+ 53% F
Dividend Return 5.85% 57% F 46% F
Total Return 0.01% 11% F 2% F
Risk Return Profile  
Volatility (Standard Deviation) 20.96% 48% F 52% F
Risk Adjusted Return 27.93% 52% F 42% F
Market Capitalization N/A N/A N/A N/A N/A

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:

There is nothing we particularly like

What to not like:
Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

High volatility

The total returns for this company are volatile and above median for its sector over the past 5 years. Make sure you have the risk tolerance for investing in such stock.